{"id":68,"date":"2025-04-02T20:16:50","date_gmt":"2025-04-02T20:16:50","guid":{"rendered":"https:\/\/ri.idigh.ca\/rd2025\/?page_id=68"},"modified":"2026-04-23T13:34:54","modified_gmt":"2026-04-23T17:34:54","slug":"speakers","status":"publish","type":"page","link":"https:\/\/ri.idigh.ca\/rd2026\/speakers\/","title":{"rendered":"Keynote Speakers"},"content":{"rendered":"\n
\"\"<\/figure>
\n

Emilia Liana Falcone<\/strong><\/p>\n\n\n\n

    \n
  • Associate Clinical Professor, Department of Medicine, Universit\u00e9 de Montr\u00e9al<\/li>\n\n\n\n
  • Associate Research Professor, Montreal Clinical Research Institute (IRCM)<\/li>\n\n\n\n
  • Director, Microbiome and Mucosal Defence Research Unit, IRCM<\/li>\n\n\n\n
  • Director, IRCM Post-COVID-19 Research Clinic (IPCO)<\/li>\n\n\n\n
  • Canada Research Chair (Tier 2) in Role of the Microbiome in Inborn Errors of Immunity and Post-Infectious Conditions<\/li>\n<\/ul>\n\n\n\n


    Dr. Emilia Liana Falcone is a physician-scientist and Director of the Microbiome and Mucosal Defense Research Unit at the Montreal Clinical Research Institute (IRCM), where she also leads the IRCM Post-COVID-19 Research Clinic (IPCO), the first clinic of its kind in Quebec. Through IPCO, she has evaluated hundreds of individuals with long COVID and established a deeply phenotyped clinical cohort and biobank.<\/p>\n\n\n\n

    Her research program investigates how microbiota-derived signals shape immune and neuroimmune responses across inborn errors of immunity and post-infectious conditions. By integrating longitudinal human cohorts with gnotobiotic and mechanistic models, her work has identified pathways linking intestinal barrier dysfunction, microbial translocation, and immune dysregulation in long COVID and other immune-mediated conditions, including actionable therapeutic targets.<\/p>\n\n\n\n

    Dr. Falcone holds a Tier 2 Canada Research Chair and was recently elected to the Canadian Academy of Health Sciences as an Emerging Leader. She serves as Content Chair for the Canadian Guidelines for Post-COVID-19 Condition and has contributed to national and federal initiatives, including the Chief Science Advisor\u2019s Task Force on Post-COVID-19 Condition. Her work has also been presented to the House of Commons of Canada.<\/p>\n\n\n\n

    She is an attending physician in Infectious Diseases at the Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM) and leads a translational research program at the interface of microbiome science, mucosal immunology, and infectious diseases.
    <\/p>\n<\/div><\/div>\n\n\n\n

    \"\"<\/figure>
    \n

    Marina Klein<\/strong><\/p>\n\n\n\n

      \n
    • Full Professor, Department of Medicine, Division of Infectious Diseases, McGill University<\/li>\n\n\n\n
    • Research Director, Chronic Viral Illnesses Service, McGill University<\/li>\n\n\n\n
    • Senior Scientist, Infectious Diseases and Immunity in Global Health Program, RI-MUHC<\/li>\n\n\n\n
    • Tier 1 Canada Research Chair in Clinical and Epidemiologic Studies of Chronic Viral Infections in Vulnerable Populations<\/li>\n\n\n\n
    • National Director, CTN+ (CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research)<\/li>\n<\/ul>\n\n\n\n


      Dr. Marina B. Klein is Professor of Medicine at McGill University, Division of Infectious Diseases and Chronic Viral Illnesses Service, where she is Research Director. She is the National Director of the CIHR Canadian HIV\/AIDS & STBBI Clinical Trials Network (CTN+) and holds a Tier 1 Canada Research Chair. Dr. Klein\u2019s research program builds on 20 years of multidisciplinary work leading one of the largest cohorts focused on HIV and HCV coinfection in the world (Canadian Coinfection Cohort) and her leadership in clinical trials. She has served as a principal investigator, leader and and collaborator on major national and international collaborative cohort study initiatives. Recently she led Platinum Can (CTN338), a randomized controlled feasibility trial evaluating tecovirimat for the emerging infectious disease, mpox, and collaborated with colleagues internationally across 16 countries to assemble the largest mpox case series with an accompanying atlas published in the NEJM in 2023.<\/p>\n\n\n\n

      <\/p>\n<\/div><\/div>\n\n\n\n

      <\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-68","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/pages\/68","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/comments?post=68"}],"version-history":[{"count":132,"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/pages\/68\/revisions"}],"predecessor-version":[{"id":848,"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/pages\/68\/revisions\/848"}],"wp:attachment":[{"href":"https:\/\/ri.idigh.ca\/rd2026\/wp-json\/wp\/v2\/media?parent=68"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}